Tailoring Myelofibrosis Care With the Latest Molecular Discoveries

In roundtable discussion around patient-centered treatment of myelofibrosis (MF) led by Prithviraj Bose, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, experts explore the latest advancements in the molecular biology of MF. The conversation brings together a distinguished panel of researchers and clinicians:

• Idoroenyi Amanam, MD, assistant professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
• Naseema Gangat, MBBS, professor of medicine and a consultant, Department of Hematology, Mayo Clinic
• Pankit J. Vacchani, MD, assistant professor of medicine and associate scientist of experimental therapeutics, University of Alabama at Birmingham

The panel examines emerging insights into the genetic drivers of MF, including key mutations in JAK2, CALR, and MPL, and how these mutations influence disease prognosis and therapeutic decisions.